Durham NC 非小细胞肺癌临床试验
39项针对 非小细胞肺癌的研究正在 Durham及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])
招募中3 期
- Duke University Medical Center, Durham
A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment
招募中2 期
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 距离 10 英里
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- Duke University, Durham
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
招募中1 期
- Exelixis Clinical Site #12, Durham
A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)
招募中3 期
- UNC Lineberger Comprehensive Cancer Center ( Site 3250), Chapel Hill · 距离 10 英里
Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial
招募中3 期
- Durham VA Medical Center, Durham
- Duke University Medical Center, Durham
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
招募中3 期
- Duke Cancer Center, Durham
A Study of PHN-012 in Patients With Advanced Solid Tumors
招募中1 期
- PHN-012-001 Site, Durham
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
招募中3 期
- UNC Lineberger Comprehensive Cancer Center at University of North Carolina, Chapel Hill · 距离 10 英里
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
招募中3 期
- Duke University Medical Center, Durham
A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)
招募中2 期
- University of North Carolina at Chapel Hill, Chapel Hill · 距离 10 英里
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
招募中1/2 期
- Duke Cancer Center Durham, Durham
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
招募中3 期
- Clinical Study Site, Durham
- Clinical Study Site, Chapel Hill · 距离 10 英里
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
招募中3 期
- Durham VA Health Care System, Durham
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
招募中1/2 期
- Duke University School of Medicine, Durham
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
招募中2/3 期
- Duke University Medical Center, Durham
Effects of Infusion Timing on Treatment Response in Solid Tumors
招募中2 期
- University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill · 距离 10 英里
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
招募中观察性研究
- UNC- Chapel Hill, Chapel Hill · 距离 10 英里
A Phase 1/1b Study of IAM1363 in HER2 Cancers
招募中1 期
- Duke Cancer Institute, Durham
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
招募中3 期
- Duke Cancer Institute, Durham
- University of North Carolina Medical Center, Chapel Hill · 距离 10 英里
Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
招募中1 期
- University of North Carolina - Gastroenterology and Hepatology, Chapel Hill · 距离 10 英里
- University of North Carolina, Chapel Hill · 距离 10 英里
A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
招募中1/2 期
- Duke Cancer Institute, Durham
Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-small Cell Lung Cancer
招募中2 期
- UNC Health - University of North Carolina, Chapel Hill · 距离 10 英里
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
招募中1 期
- Duke University Medical Center, Durham
A Study of BH-30643 in Subjects With Locally Advanced or Metastatic NSCLC Harboring EGFR and/or HER2 Mutations
招募中1/2 期
- Duke Cancer Institute, Durham
AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors
招募中1 期
- Duke Cancer Center, Durham
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
招募中2 期
- University of North Carolina, Chapel Hill · 距离 10 英里
Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan
招募中1 期
- Duke Cancer Institute /ID# 276267, Durham
First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors
招募中1 期
- Research Site, Durham
A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
招募中1 期
- Research Site, Durham
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
招募中1 期
- Duke Cancer Center /ID# 251975, Durham
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
招募中2 期
- Durham VA Medical Center, Durham
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
招募中1 期
- Duke Cancer Center, Durham
Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
招募中2/3 期
- Durham VA Medical Center, Durham
Veterans Affairs Lung Cancer Surgery Or Stereotactic Radiotherapy
招募中
- Durham VA Medical Center, Durham, NC, Durham
Autologous CAR T-Cells Targeting the GD2 Antigen for Lung Cancer
招募中早期 I 期
- Lineberger Comprehensive Cancer Center, Chapel Hill · 距离 10 英里
GEMINI-NSCLC: NSCLC Biomarker Study
招募中观察性研究
- Duke University, Durham
- UNC, Chapel Hill · 距离 10 英里
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
招募中观察性研究
- Massive Bio SYNERGY-AI site, Chapel Hill · 距离 10 英里
A Study of NX-1607 in Adults With Advanced Malignancies
招募中1 期
- University of North Carolina, Chapel Hill · 距离 10 英里
其他城市的 非小细胞肺癌试验
- Houston, TX145 项研究
- New York City, NY121 项研究
- Arlington, VA104 项研究
- Nashville, TN97 项研究
- Boston, MA90 项研究
- Los Angeles, CA87 项研究
- St. Louis, MO73 项研究
- Chicago, IL61 项研究
- Baltimore, MD60 项研究
- San Antonio, TX59 项研究
- Columbus, OH57 项研究
- Washington, DC55 项研究
Durham的其他研究
- 乳腺癌64 项研究
- 癌症（所有类型）58 项研究
- 多发性骨髓瘤37 项研究
- 急性髓系白血病33 项研究
- 转移性癌症33 项研究
- 前列腺癌32 项研究
- 肺癌32 项研究
- 结直肠癌28 项研究
- 卵巢癌27 项研究
- 慢性淋巴细胞白血病27 项研究
- 心力衰竭26 项研究
- 胰腺癌24 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。